Borchmann P, Goergen H, Kobe C, et al. Treatment reduction in patients with advanced-stage Hodgkin lymphoma and negative interim PET: final results of the international, randomized phase 3 trial HD18 by the German Hodgkin Study Group. EHA 2017, abstract S150.
Rituximab of obinutuzumab of plus CHOP bij nieuw-gediagnostiseerd DLBCL
aug 2017 | Lymfoom